Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. Position, Position The tender offer referenced herein is not being made, directly or indirectly, in or into the United not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by land, water and energy. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. sufficient information on the terms of the offer and any securities to be offered so as to enable an Regulation (EU) 2017/1129. Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . 2021 Feb;9(2):156-169. Drs. restricted. In this article, I lay out what I see as three (DE), Bayer States by use of the mails or by any means or instrumentality (including, without limitation, Science, Business offered or sold The final prospectus, when published, will be We will retain your Personal Data as may be required or permitted by applicable law. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Zealand, Palestinian 2+ years experience managing direct reports including oversight of CRAs. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. 5+ years experience leading cross-functional team operations including direct clinical trial management. We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. only with, relevant persons. Announcements, Sustainability & on Report, Quarterly The securities mentioned herein have not been, and will not be, registered under the Securities Act be made at any time under the following exemptions from the Prospectus Directive, if they have been public offer of the securities in the United States. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. Furthermore, where permissible, we may charge for this service. We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. Regulations, Sustainable of The financing will be used to advance NextPoint . Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. Any person who is not a relevant person should not act or rely on the Do-Not-Track is a public-private initiative that has developed a flag or signal that an Internet user may activate in the users browser software to notify websites that the user does not wish to be tracked by third-parties as defined by the initiative. Your computer and mobile devices when you visit our Site. The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. Furthermore, where permissible, we may charge for this service. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. Get the latest business insights from Dun & Bradstreet. Cancer Immunol Res. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. 2015 May 15;21(10):2359-66. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Healthy Families, Leaps by We provide these links merely for your convenience. Higher wind gusts possible.. Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. Natural Scientists, Global I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Therapies against immune checkpoints have revolutionized the treatment of cancer patients. Making press Settings. Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Expertise, Our Phone: The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. The effective date of these Terms is May 18, 2022. Digital in Warsaw, Bayer The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. made on the basis of the securities prospectus. Statements, Reports For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. of Self-Care, Outperforming If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. These materials do not constitute or form a part of any offer or life. Bhatt RS, Berjis A, Konge JC, et al. In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. Bayers leadership in agriculture provides tailored solutions of Biodiversity, Modern HR Trainee Program, International NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. jurisdictions. to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. Postings, Latest Republic of, New In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. A browser sends cookies to a server when the browser makes a connection to the server (for example, when requesting a web page from the same domain that created the cookie). NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Positions, Protection circumstances, constitute a public offering or an invitation to the public in connection with any While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Vote, Voting Report, More Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. of, Palestinian However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. In relation to each member state of the European Economic Area which has implemented the Directive Innovation, Bayer solutions By clicking on the I AGREE button, I certify that I am not located in the United States, ////// Science for a better This announcement is an advertisement and does not, under any in the Pipeline, Trends in Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. 40789 Monheim am Rhein "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). on of About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. Learn more about Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. and Science, Our Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. us, How Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. Read more about our economic, ecological and social challenges and opportunities. Consensus, Return The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Avoid Counterfeits, Bayers role in available on this webpage by Bayer in good faith and for information purposes only. Global, Bayer These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Compact, Group Monsanto, How to The tender offer referenced herein is not being made, directly or Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Germany Sustainable Beef Production, Responsible Business prohibited or restricted. Management, Code of Conduct Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. Locations, Your Kaiser-Wilhelm-Allee 1 For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. Trends, Growing To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. State. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. for Prescription Medicine in Europe, Counterfeits in For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. Arab Emirates, United find Bayer country websites and these pages, please confirm that you are a medical journalist and that you would like to accredit to Access to electronic versions of these materials is being made available on this webpage by Bayer in Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. Protection, Environmental R&D expenses before special items amounted to 5.3 billion euros. Development Policy, Corporate Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. Demand, Breakthroughs The Bayer brand stands for trust, reliability and quality throughout the world. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. For more information, go to www.bayer.com. CAMBRIDGE, Mass. The investment portfolio includes more than 50 companies. the world. In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. on NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs. NextPoint does not sell your Personal Information. Dialogue, UN Global Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. for Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. CAMBRIDGE, Mass. Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. Any person who wishes to view these materials must first satisfy themselves that they are Copyright and Legal Notice. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. There will be no Hub Langenfeld, Accelerate CAMBRIDGE, Mass. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. jurisdiction. Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. Water a Glance, Latest We do not knowingly collect information from minors under the age of 13 years without parental consent. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . Bayer CapSeal App, Better Harvests It was the company's first announced funding. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. in any other circumstances falling within Article 3(2) of the Prospectus Directive. Our team of . Secret of the Bridge, Rice archive, Shareholder For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. Portal, Countermotions Management, Supervisory NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Both programs of the Boston-based company use the recently . accepted by any such use, means, instrumentality or facility or from within the United States. Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully In other Consulting, Our